Top

International Journal of Mental Health and Addiction

Published in:

01-04-2022 | Psychotherapy | Clinical Case Studies

Classic Psychedelics as a Psychotherapeutic Aid in the Treatment of Stimulant Use Disorder: a Case Report

Authors: Shevaugn Johnson, Quentin C. Black

Published in: International Journal of Mental Health and Addiction | Issue 2/2022

Abstract

Despite nascent research supporting the efficacy of classic psychedelics as a psychotherapeutic aid for the treatment of substance abuse, to date, there is limited published research exploring their use in the treatment of stimulant use disorder and dual diagnosis. A 22-year-old male with a history of mood disorder and polysubstance use presented to a private Australian mental health clinic. While undergoing psychological treatment for mood and stimulant use disorder, this patient reported significant benefit from his use of classic psychedelics. Following consumption of 3.5 grams of psilocybin-containing mushrooms, he decided to seek out psychotherapy for the first time. Throughout treatment, subjective reports of his classic psychedelic use, which among others, included two occasions of having consumed 200 μg of lysergic acid diethylamide and 100 mg of dimethyltryptamine, were recorded and a psychometric tool used to capture mystical experiences was administered. As treatment progressed, the patient reported being better able to consolidate his therapeutic gains through the integration of insights obtained through his use of classic psychedelics, ultimately remaining abstinent from all stimulant drugs. The results of this case report suggest that classic psychedelics may be effective psychotherapeutic aids to be used in traditional substance abuse treatment programs. It is hoped that this case report will inform future research in this field.

American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders (5th ed.).

Amoroso, T., & Workman, W. (2016). Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. Journal of Psychopharmacology, 30, 595–600. https://doi.org/10.1177/0269881116642542.CrossRefPubMed

Argento, E., Strathdee, S. A., Tupper, K., Braschel, M., Wood, E., & Shannon, K. (2017). Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting. BMJ Open, 7(9), e016025. https://doi.org/10.1136/bmjopen-2017-016025.CrossRefPubMedPubMedCentral

Barker, E. L. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/10.1124/pr.115.011478.CrossRef

Barrett, F., Johnson, M., & Griffiths, R. R. (2015). Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 1182–1190. https://doi.org/10.1177/0269881115609019.CrossRefPubMed

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. https://doi.org/10.1177/0269881114565144.CrossRefPubMed

Bogenschutz, M. P., Podrebarac, S. K., Duane, G. H., Amegadzie, S. S., Malone, T. C., Owens, L. T., et al. (2018). Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder. Frontiers in Pharmacology, 9, 100. https://doi.org/10.3389/fphar.2018.00100.CrossRefPubMedPubMedCentral

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America, 109(6), 2138–2143. https://doi.org/10.1073/pnas.1119598109.CrossRefPubMedPubMedCentral

Carhart-Harris, R. L., Leech, R., Erritzoe, D., Williams, T., Stone, J. M., Evans, J., et al. (2013). Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis. Schizophrenia Bulletin, 39(6), 1343–1351. https://doi.org/10.1093/schbul/sbs117.CrossRefPubMed

Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., Leech, R., Williams, L. T., Williams, T. M., Bolstridge, M., Sessa, B., McGonigle, J., Sereno, M. I., Nichols, D., Hellyer, P. J., Hobden, P., Evans, J., Singh, K. D., Wise, R. G., Curran, H. V., Feilding, A., & Nutt, D. J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences of the United States of America, 113(17), 4853–4858. https://doi.org/10.1073/pnas.1518377113.CrossRefPubMedPubMedCentral

Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, N., Wall, M. B., et al. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 7, 13187. https://doi.org/10.1038/s41598-017-13282-7.CrossRefPubMedPubMedCentral

Chomchai, C., & Chomchai, S. (2015). Global patterns of methamphetamine use. Current Opinion in Psychiatry, 28(4), 269–274. https://doi.org/10.1097/YCO.0000000000000168.CrossRefPubMed

Danforth, A., Grob, C., Struble, C., Feduccia, A., Walker, N., Jerome, L., et al. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235, 3137–3148. https://doi.org/10.1007/s00213-018-5010-9.CrossRefPubMedPubMedCentral

Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2015). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews, 7(3), 157–164.CrossRef

Garcia-Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020). Persisting reductions in Cannabis, opioid, and stimulant misuse after naturalistic psychedelic use: An online survey. Frontiers in Psychiatry, 10, 955.CrossRef

Gossop, M., Darke, S., Griffiths, P., Hando, J., Powis, B., Hall, W., & Strang, J. (1995). The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction, 90(5), 607–614. https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1360-0443.1995.9056072.x.

Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U. D., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attributionof personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632. https://doi.org/10.1177/0269881108094300.

Hendricks, P.S. (2018) Psilocybin treatment of cocaine use disorder. Symposium presented at: 80th Annual Meeting of the College on Problems of Drug Dependence; June 11, San Diego, CA.

Hendricks, P. S., Thorne, C. B., Clark, B. C., Coombs, D. W., & Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29(3), 280–288. https://doi.org/10.1177/0269881114565653.CrossRefPubMed

Inserra, A. (2019). Current status of psychedelic therapy in Australia and New Zealand: Are we falling behind? Australia and New Zealand Journal of Psychology, 53(3), 190–192. https://doi.org/10.1177/0004867418824018.CrossRef

Johnson, S., & Black, Q.C. (2020). Classic psychedelics in the treatment of stimulant use disorder: a case report [dataset]. Figshare. https://doi.org/10.6084/m9.figshare.11345024.

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT_2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992. https://doi.org/10.1177/0269881114548296.CrossRefPubMed

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2017). Long-term follow-up of psilocybin-facilitated smoking cessation. The American Journal of Drug and Alcohol Abuse, 43(1), 55–60. https://doi.org/10.3109/00952990.2016.1170135.CrossRefPubMed

Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010). Pharmacological approaches to methamphetamine dependence: a focused review. British Journal of Clinical Pharmacology, 69(6), 578–592. https://doi.org/10.1111/j.1365-2125.2010.03639.x.CrossRefPubMedPubMedCentral

Krebs, T. S., & Johansen, P. O. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994–1002. https://doi.org/10.1177/0269881112439253.CrossRefPubMed

Ludwig, A. M., & Levine, J. (1965). A controlled comparison of five brief treatment techniques employing LSD, hypnosis, and psychotherapy. American Journal of Psychotherapy, 19(3), 417–435. https://doi.org/10.1176/appi.psychotherapy.1965.19.3.417.CrossRefPubMed

MacLean, K., Leoutsakos, J., Johnson, M. W., & Griffiths, R. R. (2012). Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. Journal for the Scientific Study of Religion, 51(4), 721–737. https://doi.org/10.1111/j.1468-5906.2012.01685.x.CrossRefPubMedPubMedCentral

Morgan, L. (2020). MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn’t. Annals of General Psychiatry, 19(33), 1–7. https://doi.org/10.1186/s12991-020-00283-6.CrossRef

Nielson, E. M., May, D. G., Forcehimes, A. A., & Bogenschutz, M. P. (2018). The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Frontiers in Pharmacology, 9, 132. https://doi.org/10.3389/fphar.2018.00132.CrossRefPubMedPubMedCentral

Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015). The psychedelic state induced by Ayahuasca modulates the activity and connectivity of the default mode network. PLoS One, 10(2), e0118143. https://doi.org/10.1371/journal.pone.0118143.CrossRefPubMedPubMedCentral

Rawson, R. A., Gonzales, R., & Brethen, P. (2002). Treatment of methamphetamine use disorders: an update. Journal of Substance Abuse Treatment, 23(2), 145–150. https://doi.org/10.1016/S0740-5472(02)00256-8.CrossRefPubMed

Savage, C., & McCabe, O. L. (1973). Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. Archives of General Psychiatry, 28(6), 808–814. https://doi.org/10.1001/archpsyc.1973.01750360040005.CrossRefPubMed

Thomas, G., Lucas, P., Capler, N. R., Tupper, K. W., & Martin, G. (2013). Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Current Drug Abuse Reviews, 6(1), 30–42.CrossRef

Wheeler, S.W., & Dyer, N.L. (2020). A systematic review of psychedelic-assisted psychotherapy for mental health: an evaluation of the current wave of research and suggestions for the future. Psychology of Consciousness: Theory, Research, and Practice. https://doi.org/10.1037/cns0000237

Title: Classic Psychedelics as a Psychotherapeutic Aid in the Treatment of Stimulant Use Disorder: a Case Report
Authors: Shevaugn Johnson
Quentin C. Black
Publication date: 01-04-2022
Publisher: Springer US
Keyword: Psychotherapy
Published in: International Journal of Mental Health and Addiction / Issue 2/2022
Print ISSN: 1557-1874
Electronic ISSN: 1557-1882
DOI: https://doi.org/10.1007/s11469-020-00398-7

At a glance: The STEP trials

Springer Medicine

Classic Psychedelics as a Psychotherapeutic Aid in the Treatment of Stimulant Use Disorder: a Case Report

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Psychometric Evidence of the 7-Item Generalized Anxiety Disorder Questionnaire in Brazil

Depression and Disordered Gaming: Does Culture Matter?

Screening Performance of the Korean Version of the Gambling Problem Severity Subscale of the Canadian Adolescent Gambling Index (CAGI GPSS)

Size Estimation of People Who Inject Drugs and Their Geographical Distribution in Dogonbadan, Iran, During 2018: a Mapping Method

Land-Based Healing: Toward Understanding the Role of Elders

Integrating a Co-occurring Disorders Intervention in a Rural Drug Treatment Court: Preliminary 6-Month Outcomes and Policy Implications